The 2026 European Association for the Study of Diabetes ("EASD") annual meeting in Milan has become the stage for a fierce data duel between Eli Lilly LLY and Novo Nordisk NVO. Both pharma giants unveiled new clinical evidence to bolster their positions in the booming weight-loss drug market. Lilly presented full Phase 3 data for its triple-G drug retatrutide, showing that 34.9% of patients on the highest dose lost at least 25% of their body weight, alongside a new combination drug, EloraTZP, that delivered up to 23.3% weight loss in patients with obesity and type 2 diabetes. Novo countered this with real-world data suggesting that Ozempic is associated with a 6% lower risk of major cardiovascular events compared with Lilly's Mounjaro.
Wir zeigen den wichtigsten Punkt oeffentlich. Erstellen Sie ein kostenloses Konto, um den vollstaendigen Artikel zu lesen, ihn zu speichern, zu diskutieren und mit Markt- und OSINT-Kontext zu verbinden.